Significant Short Interest Growth in TEVA
According to the latest FINRA short interest data for the settlement period ending September 15, 2026, Teva Pharmaceutical Industries (TEVA) has experienced a dramatic increase in short positioning. The data indicates that short interest has risen more than tenfold, marking a significant shift in market sentiment toward the pharmaceutical giant. While these figures are based on the bi-monthly FINRA reporting cycle and reflect positions as of mid-September, the magnitude of the increase suggests a concerted effort by institutional bears to build substantial short exposure. Investors should note that this data is backward-looking and represents open positions rather than daily flow.
Signal data sourced from StockTitan. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.